-
Mashup Score: 0IMpower010 Unveiled: A Fresh Look at Atezolizumab in Lung Cancer - 8 month(s) ago
IMpower010 & Atezolizumab: The trial has cemented the significance of atezolizumab in the potential treatment options for lung cancer, especially as an adjuvant in non-small cell lung cancer (NSCLC). Debate & Discourse: While promising, the broadened approval and usage of atezolizumab have sparked meaningf…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Dr Millie Das, MD opens a discussion surrounding updates regarding non-small cell lung cancer (NSCLC) as presented at the 2022 World Conference on Lung Cancer (WCLC).
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
In our Post Conference Perspectives series for #WCLC22, Dr Millie Das (@DasMillie11) opens a discussion surrounding updates regarding #NSCLC, including results of the #IMpower010 trial evaluating #atezolizumab vs best supportive care. https://t.co/PvxrhFWNO7 @IASLC https://t.co/yVZuOm5x2R
-
-
Mashup Score: 0WCLC 2022 Preview Episode | IASLC - 2 year(s) ago
The IASLC World Conference on Lung Cancer will be held in person this year in Vienna August 6th through 9th. Lung Cancer Considered Hosts Dr. Narjust Florez …
Source: IASLCCategories: Hem/Oncs, Latest HeadlinesTweet-
In the latest #LungCancerConsidered podcast, Dr. @NarjustFlorezMD and I preview #WCLC22 in Vienna (and virtually). Abstracts we're looking forward to (#IMpower010), upcoming events (Welcome Reception), and some tips (masks required, bring your own bags). https://t.co/y2bp6d20lA
-
-
Mashup Score: 2
IMpower010 showed a disease-free survival benefit with atezolizumab versus best supportive care after adjuvant chemotherapy in patients with resected stage II–IIIA NSCLC, with pronounced benefit in the subgroup whose tumours expressed PD-L1 on 1% or more of tumour cells, and no new safety signals. Atezolizumab after adjuvant chemotherapy offers a promising treatment option for patients with…
Source: The LancetCategories: Hem/Oncs, Latest HeadlinesTweet-
Published during #ESMO21 #IMPOWER010 PhIII Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA NSCLC ▶️N=1005, 32 mo f/u ▶️Stage II-IIIA PDL1+ (HR 0.66) 🎯 No benefit for known ALK/EGFR + cases (n=63) #lcsm https://t.co/n781lwHsid
-
In the world of oncology, #lungcancer is a top focus. The #IMpower010 trial stands out, turning heads in the #medicalcommunity. Dive into our recent article featuring Dr. Jack West's insights from #ASCO23. @JackWestMD @cityofhope https://t.co/3rpNp8ZSYz